Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress

SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced findings from a post hoc analysis of two long-term studies of INGREZZA® capsules evaluating global tardive... | May 15, 2023

Related Keywords

Canada ,Calgary ,Alberta ,Toronto ,Ontario ,Eiryw Roberts ,Neurocrine Biosciences ,Prnewswire Neurocrine Biosciences Inc ,Exchange Commission ,Neurocrine Biosciences Inc ,Nasdaq ,Facebook ,Schizophrenia International Research Society ,Linkedin ,Twitter ,Clinical Global Impression ,Change Tardive Dyskinesia ,Patient Global Impression ,Negative Syndrome Scale ,Calgary Depression Scale ,Chief Medical Officer ,Tardive Dyskinesia ,All Rights ,Nc Stock Exchange ,News ,Information ,Press Release ,Han ,Bay ,023 ,Neurocrine ,Oday ,Nnounced ,Findings ,Rom ,Most ,Oc ,Analysis ,F ,Two ,Studies ,Capsules ,Valuating ,Lobal Nbix Us64125c1099 ,